Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Corcept Therapeutics Incorporated due to significant losses following regulatory issues with the FDA [1][5]. Group 1: Investigation Background - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its new drug application for relacorilant, leading to a share price decline of approximately 50% [3]. - On January 30, 2026, a corrected CRL revealed that the FDA had previously informed Corcept of concerns regarding its clinical development program, resulting in another double-digit decline in share price [4]. Group 2: Legal and Investor Support - Johnson Fistel is assessing whether Corcept complied with federal securities laws, inviting affected investors to join the investigation [5]. - The firm offers no-cost consultations for investors who suffered losses from their investment in Corcept stock [2]. Group 3: Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, with a history of recovering significant amounts for clients [6][7].